These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 93983)

  • 1. Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study.
    Cassileth PA; Petrillo MH; Cooper RA; Katz ME
    Cancer Clin Trials; 1979; 2(4):339-43. PubMed ID: 93983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside.
    Cassileth PA; Katz ME
    Cancer Treat Rep; 1977 Nov; 61(8):1441-5. PubMed ID: 922749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.
    Wiernik PH; Schimpff SC; Schiffer CA; Lichtenfeld JL; Aisner J; O'Connell MJ; Fortner C
    Cancer Treat Rep; 1976 Jan; 60(1):41-53. PubMed ID: 1069608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of 100 acute myeloid leukemias (author's transl)].
    Fière D; Martin C; Vu Van H; Coiffier B; Felman P; Bryon PA; Favre-Gilly J; Revol L
    Sem Hop; 1979 Apr 8-15; 55(13-14):633-8. PubMed ID: 224478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
    Urabe A; Mizoguchi H; Hoshino S; Nomura T; Dan K; Toyama K; Kimura M; Ogawa T; Yamaguchi H; Mutoh Y
    Int J Hematol; 1991 Feb; 54(1):75-7. PubMed ID: 1954354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction therapy and intensive consolidation with daunorubicin, cytosine arabinoside, and 6-thioguanine in adult acute nonlymphoblastic leukemia.
    Cassileth PA; Kahn SB; Silber R; Weiler C
    Cancer Clin Trials; 1981; 4(2):125-8. PubMed ID: 7249250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 13. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in acute myelogenous leukemia.
    Gale RP
    Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin.
    Stein RS; Flexner JM
    Cancer Treat Rep; 1979; 63(11-12):2123-4. PubMed ID: 294309
    [No Abstract]   [Full Text] [Related]  

  • 17. Consolidation therapy without maintenance for acute non-lymphoblastic leukaemia.
    Roberts MM; Juttner CA; Blunden RW; Horvath N; To LB; Ho JQ; Dart GW; Kimber RJ
    Med J Aust; 1988 Feb; 148(4):181-3. PubMed ID: 3340044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study.
    Ogata K; An E; Kamikubo K; Yokose N; Tamura H; Yamada T; Gomi S; Dan K; Nomura T
    Stem Cells; 1998; 16(4):280-7. PubMed ID: 9708450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.
    Sartiano GP; Pfrimmer WJ; Turner AR
    Med Pediatr Oncol; 1978; 4(3):205-12. PubMed ID: 277748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
    Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
    Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.